Myomectomy Market - By Product (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer), By Type (Abdominal Myomectomy, Hysteroscopic Myomectomy, Laparoscopic Myomectomy), By End-use (Hospitals & Clinics, Ambulatory Surgical Centers) - Glo

Myomectomy Market - By Product (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer), By Type (Abdominal Myomectomy, Hysteroscopic Myomectomy, Laparoscopic Myomectomy), By End-use (Hospitals & Clinics, Ambulatory Surgical Centers) - Global Forecast to 2032

Myomectomy Market size is poised to expand at 8.6% CAGR from 2023-2032 driven by the ongoing development and adoption of advanced surgical technologies, such as robotic-assisted and minimally invasive techniques. Innovations, including robotic-assisted surgery, laparoscopy, and higher integration of advanced imaging techniques are transforming the demand for myomectomy procedures to offer increased precision, reduced invasiveness, and shorter recovery times for enhanced patient outcomes.

Moreover, surgeons are benefiting from improved visualization and control during the procedures, further contributing to the growing preference for technologically advanced approaches. For instance, in November 2022, Olympus introduced its new minimally invasive surgery alternative, moresolution™ Power Morcellator, produced from TROKAMED GmbH for patients undergoing low-risk hysterectomy or myomectomy. With the rising transformation of the healthcare sector, the market is poised to witness steady growth.

The myomectomy industry is segmented into product type, end-use, and region.

Based on product type, the market size from the harmonic scalpel segment is likely to showcase 8.2% CAGR from 2023-2032. Harmonic scalpel has gained prominence as it offers precision and minimal invasiveness in myomectomy procedures for reducing blood loss and enhancing patient recovery. With healthcare providers prioritizing advanced technologies to optimize surgical interventions, the demand for harmonic scalpels is expected to rise to offer reduced thermal spread and improved visualization for improved surgical outcomes.

In terms of end-use, the myomectomy industry from the ambulatory surgical centers (ASC) segment is set to attain 8.5% CAGR between 2023 and 2032. The increasing preference for outpatient procedures due to reduced hospitalization costs and quicker recovery times will contribute to the segment growth. ASCs offer more convenient and cost-effective environment for myomectomy procedures compared to traditional hospital settings. The accessibility and efficiency offered to patients and the access to streamlined workflow to healthcare providers will add to the segment growth.

Regionally, the Asia Pacific myomectomy market held sizable revenue share in 2022 and is estimated to record steady growth through 2032 owing to increasing awareness, the rising prevalence of uterine fibroids, and higher advancements in healthcare infrastructure. Additionally, with the growing female population seeking advanced healthcare solutions, the demand for myomectomy procedures is particularly rising in China and India. The influx of favorable government initiatives and the surging adoption of innovative surgical technologies will further propel the regional industry growth.